Gujarat FDA approval allows new 51,200 MT Sudeep Pharma plant to start production
SUDEEPPHRM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts more than Nifty Microcap 250 and 2.7 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sudeep Pharma received Gujarat Food and Drug Control Administration approval to start manufacturing at its new facility at 179 Nandesari, Gujarat. The plant has annual installed capacity of 51,200 MT. About 60% is allocated to existing pharma, food and nutrition products, while the rest will support newer products, including bisglycinates. Commercial supplies are expected in the second half of FY27, after customer qualification.
Approval unlocks 51,200 MT of capacity and supports diversification and growth. Earnings will depend on customer qualification and production ramp-up.